NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 12th November

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Items 1.1 to 6.1.3
2. Dr James Fotheringham (Vice-chair) Items 1.1 to 6.1.3
3. Becky Pennington Items 1.1 to 6.1.3
4. Dominic Pivonka Items 1.1 to 6.1.3
5. Dr Andrew Champion Items 1.1 to 6.1.3
6. Dr Ian Bernstein Items 1.1 to 6.1.3
7. Dr Justin Daniels Items 1.1 to 6.1.3
8. Dr Peter Baker-Gulliver Items 1.1 to 5.3.2
9. Dr Steve Edwards Items 1.1 to 6.1.3
10. Hugo Pedder Items 1.1 to 6.1.3
11. Jaqueline Tomlinson Items 1.1 to 6.1.3
12. Min Ven Teo (first two topics) Items 1.1 to 6.1.3
13. Mohamad Farhat Items 1.1 to 6.1.3
14. Professor G.J. Melendez-Torres Items 5.1 to 6.1.3
15. Richard Ballerand Items 1.1 to 6.1.3
16. Youseff Oskrochi Items 1.1 to 6.1.3

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 4.2.2

 Items 6.1 to 6.1.3

Jeremy Powell, Project Manager Items 1.1 to 4.2.2

Nigel Gumbleton, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Sharlene Ting, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Louise Jones, Administrator Items 1.1 to 4.2.2

Janet Robertson, Associate Director Items 5.1 to 5.3.2

Jennifer Upton, Project Manager Items 5.1 to 5.3.2

Alan Moore, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Kirsty Pitt, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

Marcia Miller, Administrator Items 5.1 to 5.3.2

Vonda Murray, Project Manager Items 6.1 to 6.1.3

Mary Hughes, Heath Technology Assessment Adviser Items 6.1 to 6.1.3

Rachel Williams, Heath Technology Assessment Analyst Items 6.1 to 6.1.3

Ishbel McCallum, Administrator Items 6.1 to 6.1.3

External assessment group representatives present

Joanna Lord, Southampton HTA Centre (SHTAC) Items 1.1 to 4.1.3

Jonathan Shepherd, Southampton HTA Centre (SHTAC) Items 1.1 to 4.1.3

Henry Nwankwo, Warwick Evidence Items 5.1 to 5.2.1

Yen-Fu Chen, Warwick Evidence Items 5.1 to 5.2.1

Mark Corbett, Centre for Reviews and Dissemination and Centre for Health Economics – York

 Items 6.1 to 6.1.3

Pedro Saramago Goncalves, Centre for Reviews and Dissemination and Centre for Health Economics – York

 Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Prof Mark Beresford, Consultant Clinical Oncologist, clinical expert nominated by Menarini Stemline Items 1.1 to 4.1.3

Dr Mukesh Bindlish Mukesh, Consultant Clinical Oncologist, clinical expert nominated by Menarini Stemline Items 1.1 to 4.1.3

Eleanor Pearce Willis, Policy Manager, patient expert nominated by Breast Cancer Now

Kirstin Spencer, Patient advocate, patient expert nominated by METUP UK

 Items 1.1 to 4.1.3

Peter Clark, CDF Clinical Lead Items 1.1 to 4.2.1

Professor Richard Thompson, Professor of Molecular Hepatology, Clinical expert, nominated by Mirum Pharmaceuticals Items 5.1 to 5.2.1

Mel Fernandez, Patient expert nominated by Children’s Liver Disease Foundation

 Items 5.1 to 5.2.1

Caitilin Mulholland, Patient expert nominated by Children’s Liver Disease Foundation

 Items 5.1 to 5.2.1

Ayesha Ali, NHS Commissioning Expert Items 5.1 to 5.2.1

Lucy Leeman, Consultant Clinical Immunologist, Consultant Clinical Immunologist, Clinical expert, nominated by NHS England Items 6.1 to 6.1.3

Shuaib Nasser, Consultant in Allergy and Asthma, Consultant in Allergy and Asthma, Clinical expert, nominated by ALK Items 6.1 to 6.1.3

Leonard Siew, Clinical Lead and Consultant Allergist, Clinical Lead and Consultant Allergist Clinical expert, nominated by Royal College of Physicians Items 6.1 to 6.1.3

Helen Evans-Howells, Trustee and Chair of Clinical Scientific Panel, Patient expert, nominated by Anaphylaxis UK Items 6.1 to 6.1.3

Amena Warner, Head of Clinical services, Patient expert, nominated by Allergy UK

 Items 6.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Patrick De Barr, Ravi Ramessur, Craig Buckley and Mario Ganau.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 8th October 2024.

### Appraisal of Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Menarini Stemline.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11263).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Radha Todd.
	2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11263>.

### Appraisal of Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Mirum Pharma.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10832).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Radha Todd.
	2. Part 2a – Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10832>.

### Appraisal of 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from ALK-Abello.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11355).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by James Fotheringham.
* **The meeting for topic ID6280 was suspended during the discussion section of part 1 because the committee was not quorate, and no recommendation could be made. NICE aims to bring ID6280 back to committee as soon as possible**
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11355>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 10th December and will start promptly at 9am.